SGMO Value

Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS

It is not possible to calculate the future cash flow value for
Sangamo Therapeutics. This is due to cash flow or dividend data being
unavailable. The share price is
$9.72.

PRICE RELATIVE TO MARKET

We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for
Sangamo Therapeutics's
earnings,
growth
and
assets
is considered below, and whether this is a fair price.

Price based on past earnings

Are
Sangamo Therapeutics's earnings available for a low price, and how does
this compare to other companies in the same industry?

High Growth Checks

Sangamo Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.

Sangamo Therapeutics's revenue is expected to grow significantly at over 20% yearly.

Past and Future Earnings per Share

The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.

Past performance checks

We assess
Sangamo Therapeutics's performance over the past 5 years by checking for:

Has earnings increased in past 5 years? (1 check)

Has the earnings growth in the last year exceeded that of the
Biotechs
industry? (1 check)

Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)

Is the Return on Equity (ROE) higher than 20%? (1 check)

Is the Return on Assets (ROA) above industry average? (1 check)

Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)

The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
Sangamo Therapeutics
has a total score of
0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

SGMO Health

A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).

The boxes below represent the relative size of what makes up
Sangamo Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.

Net Worth

Sangamo Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Sangamo Therapeutics's cash and other short term assets cover its long term commitments.

Balance sheet

This treemap shows a more detailed breakdown of
Sangamo Therapeutics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
checks below.

Assets

Liabilities and shares

The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.

Low level of unsold assets.

Debt is covered by short term assets, assets are 24.8x debt.

Historical Debt

Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.

SGMO Management

Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.

CEO

SandyMacrae

COMPENSATION

$4,104,428

AGE

55

TENURE AS CEO

2.9 years

CEO Bio

Dr. Alexander D. Macrae, also known as Sandy, M.B., Ch.B, Ph.D., MRCP, has been the Chief Executive Officer and President of Sangamo Therapeutics, Inc. since June 1, 2016. Dr. Macrae has nearly 20 years of experience in the pharmaceutical industry across a wide range of therapeutic areas in Europe, the United States and emerging markets. Since 2012, he has served as global medical officer of Takeda Pharmaceuticals, where he established and led the global medical office, which encompasses medical affairs, regulatory affairs, pharmacovigilance, outcomes research and epidemiology, quantitative sciences and knowledge and informatics. From 2001 to 2012, Dr. Macrae held roles of increasing responsibility at Glaxo SmithKline (GSK), where his last role was as senior vice president, emerging markets research and development (R&D). In that position, he provided expertise and resources to create a first-of-its-kind group to expand GSK's global reach by providing R&D strategies, clinical development and regulatory resources to enter emerging markets and Asia-Pacific. Earlier in his career at GSK, Dr. Macrae was vice president, business development. In that position, he was responsible for scientific assessment and business development project leadership for the neurology, psychiatry, cardiovascular and metabolic therapeutic areas. Earlier in his career, he worked for SmithKline Beecham, where he was responsible for clinical development in the therapeutic areas of neurology and gastroenterology. He has been a Director of Sangamo Therapeutics, Inc. since June 2016. He is a member of the Royal College of Physicians. He was a Wellcome Trust Advance Training Fellow at Hammersmith Hospital in London and a Howard Hughes Research Associate at Duke University Medical Center in Durham, N.C., where he conducted post-doctoral research in molecular pharmacology under the guidance of Nobel Prize winner Robert Lefkowitz. Dr. Macrae earned his Ph.D. in molecular genomics at King's College, Cambridge, under the supervision of Nobel Prize-winner Sydney Brenner. Dr. Macrae received his B.Sc. in pharmacology with first-class honors and his M.B., Ch.B. with honors from Glasgow University.

CEO Compensation

Sandy's compensation has increased whilst company is loss making.

Sandy's remuneration is higher than average for companies of similar size in United States of America.

Management Team Tenure

Average tenure and age of the
Sangamo Therapeutics
management team in years:

1.7

Average Tenure

50

Average Age

The average tenure for the Sangamo Therapeutics management team is less than 2 years, this suggests a new team.

Management Team

Sandy Macrae

TITLE

CEO, President & Director

COMPENSATION

$4M

AGE

55

TENURE

2.9 yrs

Kathy Yi

TITLE

EVP, CFO

COMPENSATION

$1M

AGE

46

TENURE

2.3 yrs

Ed Conner

TITLE

Senior VP & Chief Medical Officer

COMPENSATION

$1M

AGE

45

TENURE

2.5 yrs

Stéphane Boissel

TITLE

Executive Vice President of Corporate Strategy

COMPENSATION

$3M

AGE

50

TENURE

0.6 yrs

Ed Rebar

TITLE

Senior VP & CTO

TENURE

0.8 yrs

McDavid Stilwell

TITLE

Vice President of Corporate Communications & Investor Relations

TENURE

2.5 yrs

Heather Erickson

TITLE

Chief of Staff

TENURE

2.8 yrs

Andy Ramelmeier

TITLE

Senior VP and Chief Manufacturing & Quality Officer

TENURE

1.2 yrs

Adrian Woolfson

TITLE

Executive Vice president of Research & Development

AGE

53

TENURE

0.3 yrs

Jason Fontenot

TITLE

Senior Vice President of Cell Therapy

TENURE

0.2 yrs

Board of Directors Tenure

Average tenure and age of the
Sangamo Therapeutics
board of directors in years:

2.9

Average Tenure

62.5

Average Age

The average tenure for the Sangamo Therapeutics board of directors is less than 3 years, this suggests a new board.

SGMO News

Simply Wall St News

The Sangamo Therapeutics (NASDAQ:SGMO) Share Price Is Up 93% And Shareholders Are Holding On

Sangamo Therapeutics isn't a profitable company, so it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). … In the last 3 years Sangamo Therapeutics saw its revenue grow at 42% per year. … While the compound gain of 24% per year over three years is pretty good, you might argue it doesn't fully reflect the strong revenue growth.

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. … Happily, we note that in the last year insiders bought 11.41k shares for a total of US$146k. … In total, Sangamo Therapeutics insiders bought more than they sold over the last year

Do Directors Own Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares?

The big shareholder groups in Sangamo Therapeutics, Inc. … Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. … Taking a look at our data on the ownership groups (below), it's seems that.

Sandy Macrae became the CEO of Sangamo Therapeutics, Inc. … This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … How Does Sandy Macrae's Compensation Compare With Similar Sized Companies?

However, the trade-off is SGMO will have to follow strict debt obligations which will reduce its financial flexibility. … Zero-debt can alleviate some risk associated with the company meeting debt obligations, but this doesn’t automatically mean SGMO has outstanding financial strength. … Is SGMO right in choosing financial flexibility over lower cost of capital.

We often see insiders buying up shares in companies that perform well over the long term. … The Last 12 Months Of Insider Transactions At Sangamo Therapeutics. … In total, Sangamo Therapeutics insiders bought more than they sold over the last year

Do Institutions Own Shares In Sangamo Therapeutics Inc (NASDAQ:SGMO)?

If you want to know who really controls Sangamo Therapeutics Inc (NASDAQ:SGMO), then you'll have to look at the makeup of its share registry. … It has a market capitalization of US$1.1b, which means it would generally expect to see some institutions on the share registry. … institutions are noticeable on the share registry.

Is Sangamo Therapeutics Inc (NASDAQ:SGMO) Cheap And High Growth?

is a healthcare company operating in an industry, … The demand for new drug development to meet new or persistent chronic illnesses, as well as the ongoing need for biotech drugs as Baby Boomers continue to age, are growth drivers for the optimistic outlook for the biotech industry in the long run … Healthcare analysts are forecasting for the entire industry,

When Can We Expect A Profit From Sangamo Therapeutics Inc (NASDAQ:SGMO)?

focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. … The company’s loss has recently broadened since it announced a -US$54.57m loss in the full financial year, compared to the latest trailing-twelve-month loss of -US$58.12m, moving it further away from breakeven. … I’ve put together a brief outline of industry analyst expectations for SGMO, its year of breakeven and its implied growth rate.

When Sangamo Therapeutics Inc (NASDAQ:SGMO) announced its most recent earnings (31 December 2017), I did two things: looked at its past earnings track record, then look at what is happening in the industry. … I look at data from the most recent 12 months, which either annualizes the most recent 6-month earnings update, or in some cases, the most recent annual report is already the latest available financial data. … For Sangamo Therapeutics, its latest trailing-twelve-month earnings is -US$54.57M, which, relative to the prior year's level, has become less negative.

SGMO Company Info

Description

Sangamo Therapeutics, Inc. focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company’s zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation. Its therapeutic products which are in Phase I/II clinical trial include SB-525 for the treatment of hemophilia A; SB-FIX for the treatment of hemophilia B; ST-400 for the treatment of beta-thalassemia; and SB-318 for the treatment of Mucopolysaccharidosis Type I and SB-913 for the treatment of Mucopolysaccharidosis Type II, which are lysosomal storage disorders (LSDs). The company also develops ST-920, a gene therapy for fabry disease. It has collaboration and license agreements with Kite Pharma, Inc., Pfizer Inc., Bioverativ Inc., and Shire International GmbH, as well as license partnerships with Dow AgroSciences LLC, Sigma-Aldrich Corporation, Genentech, Inc., Open Monoclonal Technology, Inc., F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Richmond, California.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.